Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Qualit-E-SpeakPharma-Insert
    X

    Find Dermatology Drugs in Phase I Clinical Development in CANADA

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              InMed Pharmaceuticals

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial

              Contact the Supplier

              Lead Product(s): Cannabinol

              Therapeutic Area: Dermatology

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 24, 2020

              Details:

              755-102-HV will evaluate the safety and tolerability of INM-755 cream applied daily on epidermal wounds in healthy volunteers.

              InMed Pharmaceuticals

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              InMed Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN

              Contact the Supplier

              Lead Product(s): Cannabinol

              Therapeutic Area: Dermatology

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 10, 2020

              Details:

              With enrollment completed, treatment is expected to conclude towards the end of March and results are anticipated to be announced in the second half of calendar 2020.

              InMed Pharmaceuticals

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials

              Contact the Supplier

              Lead Product(s): Cannabinol

              Therapeutic Area: Dermatology

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 20, 2020

              Details:

              InMed Pharmaceuticals, revealed the rare cannabinoid cannabinol as the active pharmaceutical ingredient in its two product candidates under development: INM-755 for epidermolysis bullosa and INM-088.

              PharmaCompass__DigitalAd